Germline mutations of CDKN2A, at 9p21, are responsible for predisposition to melanoma in some families. However, evidence of linkage to 9p21 has been demonstrated in a significant proportion of kindreds with no detectable mutations in CDKN2A. It is possible that mutations in noncoding regions may be
Mutation analysis of the CDKN2A promoter in Australian melanoma families
✍ Scribed by Pamela M. Pollock; Mitchell S. Stark; Jane M. Palmer; Marilyn K. Walters; Joanne F. Aitken; Nicholas G. Martin; Nicholas K. Hayward
- Publisher
- John Wiley and Sons
- Year
- 2001
- Tongue
- English
- Weight
- 182 KB
- Volume
- 32
- Category
- Article
- ISSN
- 1045-2257
- DOI
- 10.1002/gcc.1170
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Approximately 50% of all melanoma families worldwide show linkage to 9p21‐22, but only about half of these have been shown to contain germ line CDKN2A mutations. It has been hypothesized that a proportion of these families carry mutations in the noncoding regions of CDKN2A. Several Canadian families have been reported to carry a mutation in the 5′ UTR, at position −34 relative to the start site, which gives rise to a novel AUG translation initiation codon that markedly decreases translation from the wild‐type AUG (Liu et al., 1999). Haplotype sharing in these Canadian families suggested that this mutation is of British origin. We sequenced 1,327 base pairs (bp) of CDKN2A, making up 1,116 bp of the 5′ UTR and promoter, all of exon 1, and 61 bp of intron 1, in at least one melanoma case from 110 Australian families with three or more affected members known not to carry mutations within the p16 coding region. In addition, 431 bp upstream of the start codon was sequenced in an additional 253 affected probands from two‐case melanoma families for which the CDKN2A mutation status was unknown. Several known polymorphisms at positions −33, −191, −493, and −735 were detected, in addition to four novel variants at positions 120, −252, −347, and −981 relative to the start codon. One of the probands from a two‐case family was found to have the previously reported Q50R mutation. No family member was found to carry the mutation at position −34 or any other disease‐associated mutation. For further investigation of noncoding CDKN2A mutations that may affect transcription, allele‐specific expression analysis was carried out in 31 of the families with at least three affected members who showed either complete or “indeterminate” 9p haplotype sharing without CDKN2A exonic mutations. Reverse transcription polymerase chain reaction and automated sequencing showed expression of both CDKN2A alleles in all family members tested. The lack of CDKN2A promoter mutations and the absence of transcriptional silencing in the germ line of this cohort of families suggest that mutations in the promoter and 5′ UTR play a very limited role in melanoma predisposition. © 2001 Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES
## Abstract Germline mutations in the __CDKN2A__ tumor suppressor gene located on 9p21 have been linked to development of melanomas in some families. A germline 3‐bp insertion in exon 2 of __CDKN2A__, leading to an extra arginine at codon 113 (113insR), has been identified in 17 Swedish melanoma fa
Mutation analysis of two genes involved in melanoma susceptibility (CDKN2A/p16 INK4a and CDK4) was undertaken in 131 probands with a family history of melanoma. Screening of all three exons of CDKN2A and exon 2 of CDK4 by single-strand conformation polymorphism (SSCP) analysis and/or direct sequenci
Germ-line mutations in CDKN2A have been shown to predispose to cutaneous malignant melanoma. We have identified 2 new melanoma kindreds which carry a duplication of a 24bp repeat present in the 5' region of CDKN2A previously identified in melanoma families from Australia and the United States. This
## Abstract __CDKN2A__ is a major susceptibility gene for cutaneous malignant melanoma (CMM), but the variable penetrance and clinical manifestations among mutation carriers suggest the existence of modifier factors. The goal of this study was to identify modifier genes for CMM in CMM‐prone familie
## Abstract The __CDKN2A/ARF__ genes have been associated with increased risk of malignant melanoma (MM) in families with multiple members affected by disease and in families characterized by the constellation of breast cancer and MM. The exact contribution of __CDKN2A/ARF__ to disease risk remains